(Q34019589)

English

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

21

object named as

Marc Buyse

0 references

Christine Desmedt

object named as

Christine Desmedt

2

0 references

object named as

Angelo Di Leo

1

0 references

Fátima Cardoso

object named as

Fatima Cardoso

13

0 references

object named as

Helena Earl

10

0 references

5

object named as

Bent Ejlertsen

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

16

object named as

Chris J Twelves

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

author name string

John M S Bartlett

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Fanny Piette

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Kathleen I Pritchard

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Denis Larsimont

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Christopher Poole

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Jorma Isola

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Henning Mouridsen

11

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Frances P O'Malley

12

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Minna Tanner

14

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Alison Munro

15

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Christos Sotiriou

17

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Lois Shepherd

18

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

David Cameron

19

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Martine J Piccart

20

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

HER2/TOP2A Meta-analysis Study Group

22

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

12 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1134-1142

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene-expression signatures in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2/neu in systemic therapy for women with breast cancer: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of proliferation in HER2 status predicted response to doxorubicin.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Anthracyclines: the first generation of cytotoxic targeted agents? A possible dream.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Multifactorial approach to predicting resistance to anthracyclines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970231-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70231-5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

release_wy74ovkuzzbltasfdgihewi5mm

1 reference

https://api.fatcat.wiki/v0/release/wy74ovkuzzbltasfdgihewi5mm

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34019589&oldid=1839503924"